Trial Profile
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs DNL-747 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Sanofi
- 08 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 12 May 2020 Planned End Date changed from 26 May 2021 to 1 Jun 2021.
- 02 Apr 2020 According to a Denali Therapeutics media release, Denali continues to collect data from the ongoing Phase 1b open-label extension study in ALS. Analysis of data from these trials is underway and Denali is on track to decide on next steps with DNL747 by mid-2020 together with its partner Sanofi